Harvard has partnered Deerfield to launch commercialisation firm Lab1636 with $100m in funding in order to advance life science projects towards the clinic and establish spinouts.

OUP has closed an oversubscribed third fund that it expects will invest in 40 to 50 spinouts, primarily originating from 19 core partner institutions.

The accelerator will support up to 12 health projects at a time, led by innovators including UW Health faculty and with resources provided by four partners including Warf.

Garwood Medical Devices is developing two therapeutic electrode-powered products based on licences from University of Buffalo, having last raised $3.6m in 2016.

Founding investor Lundbeckfonden Emerge returned to co-lead a series A round for the gene editing drug developer with Life Science Partners.

Medical device producer Oscor has led the heart disease treatment system developer's $20m series D round in connection with a strategic partnership.

Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.

The seed capital will help UAB-founded TriAltus Bioscience commercialise its protein purification materials, which are already being used by research clients in the US, Brazil and EU.

Abiomed-backed Shockwave Medical has raised approximately $97m in an oversubscribed initial public offering, before its shares climbed more than 85% by the end of Friday.

Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.